Gilead: Expansion Of Livdelzi For PBC Continues With European Marketing Approval
Gilead Sciences sees strong growth in HIV & oncology with BIKTARVY & TRODELVY. Learn about upcoming drugs & market potential ...
Plus Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Business Highlights
The Company recognized $5.8 million in grant revenue in the year ending December 31, 2024 and $4.9 million for the year ending December 31, 2023, which in both periods represents CPRIT’s share of the ...
pharmaphorum5d
GSK drug raises hopes for patients with PBC itch
GSK has reported promising results with a drug to treat the severe itching that plagues patients with rare cholestatic liver disease primary biliary cholangitis (PBC). Interim results from the ...
Mirum Pharmaceuticals: Set Fair For Share Price Momentum - Reversing My Sell Call
Mirum Pharmaceuticals stock surged 25% and how LIVMARLI drives growth. Explore future prospects with Volixibat. Click here to ...
Takeaways on AP's report on intense new US airstrike campaign targeting Yemen's Houthi rebels
DUBAI, United Arab Emirates (AP) — The Trump administration promised a tougher stance against Yemen’s Houthi rebels, and its ...
New US airstrike campaign targeting Yemen's Houthi rebels more intense than last, AP review finds
A new American airstrike campaign against Yemen’s Houthi rebels appears more intense and more extensive, as the U.S. moves ...
pharmaphorum3d
FDA clears Ipsen’s primary biliary cholangitis drug
PBC can worsen over time if not effectively treated, leading to liver transplant and – in some cases – premature death. Ipsen has set a list price for the drug of around $11,500 per month ...
Le Lézard14h
LIVMARLI Now Approved in Japan for ALGS and PFIC
Mirum Pharmaceuticals, Inc. today announced that its partner, Takeda Pharmaceutical Company Limited, has received approval by the Japanese Ministry of Health, Labour, and Welfare for LIVMARLI® ...
Le Lézard3d
Abbott Initiates New Intravascular Lithotripsy Clinical Trial to Improve Outcomes in Patients with Coronary Artery Disease
Abbott today announced that the U.S. Food and Drug Administration (FDA) has approved an investigational device exemption (IDE) for its Coronary Intravascular Lithotripsy (IVL) System to evaluate the ...
Medscape2d
Guidelines for Therapy of Autoimmune Liver Disease
For primary biliary cirrhosis, ursodeoxycholic acid is safe ... for hepatitis B virus and interferon for hepatitis C virus. For drug-induced liver injury or alcohol-related liver diseases ...